We are live on ! Find out more
INM icon

InMed Pharmaceuticals
INM

11 hedge funds and large institutions have $515K invested in InMed Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more capital invested

Capital invested by funds: $342K → $515K (+$173K)

4.92% more ownership

Funds ownership: 2.57% → 7.49% (+4.9%)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

21% less funds holding

Funds holding: 14 → 11 (-3)

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

Holders
11
Holders Change
-3
Holders Change %
-21.43%
% of All Funds
0.18%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
1
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$731K
2
Citadel Advisors
Citadel Advisors
Florida
+$9.95K
3
Renaissance Technologies
Renaissance Technologies
New York
+$3.44K

Top Sellers

Rank Fund Capital Flow
1
Two Sigma Advisers
Two Sigma Advisers
New York
-$81.1K
2
EAM
Empery Asset Management
New York
-$58K
3
Two Sigma Investments
Two Sigma Investments
New York
-$37K
4
TSS
Two Sigma Securities
New York
-$17K
5
Millennium Management
Millennium Management
New York
-$13K

INM Hedge Fund Activity: Q2 2022 in Review

11 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in InMed Pharmaceuticals (INM) for Q2 2022, worth a combined $515K — up 50% from $342K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of INM and 2 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 1 added.

The largest buyer was Armistice Capital, opening a new position worth an estimated $731K. The largest seller was Two Sigma Advisers, cutting an estimated $81.1K.

  • 11 institutional investors held InMed Pharmaceuticals (INM) as of Q2 2022, down from 14 in Q1 2022.
  • Funds reported $515K of InMed Pharmaceuticals stock for Q2 2022, up 50% quarter-over-quarter.
  • 2 funds opened new InMed Pharmaceuticals positions in Q2 2022 and 5 closed out, a net change of -3 holders.
  • The largest InMed Pharmaceuticals buyer in Q2 2022 was Armistice Capital, an estimated $731K added.
  • The largest InMed Pharmaceuticals seller in Q2 2022 was Two Sigma Advisers, an estimated $81.1K sold.

Based on aggregated 13F filings for Q2 2022.